Potential New Alzheimer's Drug Shows Promise

Intellect Neuroscience announced that a Phase 1b clinical trial of OXIGON (OX1) showed that this Alzheimer’s drug is safe and well tolerated at all dosages.

as reported by Intellect Neuroscience, which is a biopharmaceutical company with headquarters in New York. Intellect Neuroscience announced that a Phase 1b clinical trial of OXIGON (OX1) showed that this Alzheimer’s drug is safe and well tolerated at all dosages. OX1 is a potential treatment for Alzheimer’s disease. It inhibits the activity of beta amyloid acids. These acids are a type of amino acid that is thought to be related to the development of harmful protein plaques found in Alzheimer's disease patients. This drug,OX1, has also been shown to protect the brain from damage to the cell membranes and DNA which is caused by oxygen-containing molecules found in the body. The trial is sponsored by Intellect Neurosciences. In the trial there were three groups of 12 healthy volunteers who are older than 60. While the trial of OX1 was going on, eight subjects were given this drug at doses of 200, 400 or 800 mg daily and four received a placebo, The results of the study showed that OX1 was tolerated well and safe at each dose level.. Alzheimer's disease is the most common form of dementia, Its main characteristic is the progressive loss of memory, judgment, reasoning, and speech as other mental functions. Eventually people with Alzheimer’s disease become debilitated and eventually die from the disease or its complications. At the current time drugs used to treat Alzheimer’s disease only temporarily slow the progression of it. There are no drugs on the market today stop the progression of the disease. Besides the OX1, Intellect is working on IN-N01, an antibody that helps eliminate beta amyloid; and RECALL-VAX, a drug that may delay or prevent Alzheimer's disease in people who are at risk to develop it. Further study is needed on all these medications.